[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2008, 34(6) 382-384 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
����Ǵ���ϵͳ��;T�ܰ�ϸ����ϸ������
���������������
������
�����
PubMed
Article by
Article by

ϸ������T�ܰ�ϸ����ؿ�ԭ-4��SLE

������ �����

����ҽѧԺ�ڶ�����ҽԺ ����ҽѧԺ�ڶ�����ҽԺ

ժҪ��

ϸ������T�ܰ�ϸ����ؿ�ԭ-4�ɱ��������ϸ��Ϊ���Ķ���ϸ����ϸ������T��ϸ����ؿ�ԭ-4 Ig�Ϳ�������ϸ������T��ϸ����ؿ�ԭ-4���ڷ������������Լ�������ֲ�ų⼰���������ַ��ӣ���Ч���ڶ���ʵ�鼰�ٴ�Ӧ�����ѵõ�֤ʵ��SLE��һ�ֳ������ۼ����������������Լ�����������ѧ������Tϸ����Ӧ�����Bϸ�����Ե����ϰ����Ӷ�����Bϸ���߻��ԺͲ������������塣

�ؼ����� ����Ǵ���ϵͳ��;T�ܰ�ϸ����ϸ������  

Cytotoxic T lymphocyte-associated molecule-4 and systemic lupus erythematosus

Abstract:

Cytotoxic T lymphocyte-associated molecule-4 ��CTLA-4��, a member of B7/CD28 family, is expressed mainly by immune cells. It has multiple immunologic effects and plays a central role in down-regulating immune responses. Animal experiments and clinical practices have confirmed the efficacy of CTLA-4 immunoglobulin and anti-CTLA-4 monoclonal antibody in the prevention and treatment of autoimmune diseases, transplantation rejection and tumors. Systemic lupus erythematosus ��SLE��, a common autoimmune disease involving multiple organs, is immunologically characterized by dysfunction of T cells and dysregulation of B-cell activity, which leads to an increase in the activity of and autoantibody production by B cells.

Keywords: systemic lupus erythematosus  
�ո����� 2008-04-01 �޻����� 2008-05-24 ����淢������  
DOI:
������Ŀ:

ͨѶ����: �����
���߼��:

�ο����ף�
�������������

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־